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Placebo exhibits beneficial effects on pain perception in human experimental studies.
Most of these studies demonstrate that placebo significantly decreased neural
activities in pain modulatory brain regions and pain-evoked potentials. This study
examined placebo analgesia-related effects on spontaneous brain oscillations. We
examined placebo effects on four order-fixed 20-min conditions in two sessions:
isotonic saline-induced control conditions (with/without placebo) followed by hypertonic
saline-induced tonic muscle pain conditions (with/without placebo) in 19 subjects
using continuous electroencephalography (EEG) recording. Placebo treatment exerted
significant analgesic effects in 14 placebo responders, as subjective intensity of pain
perception decreased. Frequency analyses were performed on whole continuous EEG
data, data during pain perception rating and data after rating. The results in the first
two cases revealed that placebo induced significant increases and a trend toward
significant increases in the amplitude of alpha oscillation during tonic muscle pain
compared to control conditions in frontal-central regions of the brain, respectively.
Placebo-induced decreases in the subjective intensity of pain perception significantly
and positively correlated with the increases in the amplitude of alpha oscillations during
pain conditions. In conclusion, the modulation effect of placebo treatment was captured
when the pain perception evaluating period was included. The strong correlation
between the placebo effect on reported pain perception and alpha amplitude suggest
that alpha oscillations in frontal-central regions serve as a cortical oscillatory basis of the
placebo effect on tonic muscle pain. These results provide important evidence for the
investigation of objective indicators of the placebo effect.
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INTRODUCTION
Placebo effects on pain perception were characterized using numerous hemodynamic (e.g.,
functional magnetic resonance imaging (fMRI) and positron emission tomography (PET))
and electrophysiological (e.g., electroencephalography (EEG) and magnetoencephalography
(MEG)) in previous studies (Wager et al., 2004, 2006; Lorenz et al., 2005; Zubieta et al., 2005;
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Scott et al., 2008; Tracey, 2010). Most of these studies
demonstrated that placebo analgesia significantly decreased
neural activities in pain modulatory brain regions, including
thalamus, insula, and anterior cingulate cortex (ACC; Wager
and Fields, 2011). Laser-evoked potentials (LEPs) are one of
the best tools to assess the function of nociceptive pathways in
physiological and clinical settings (Bromm and Treede, 1991;
Iannetti et al., 2001), and LEPs were used in previous studies
to investigate placebo analgesia (Wager et al., 2006; Watson
et al., 2007). These studies demonstrated a clear decrease in P2
amplitude using LEPs (Wager et al., 2006), which suggests that
the placebo treatment affected early nociceptive processing (e.g.,
attention and affect). One recent study reported that placebo
analgesia during phasic pain was associated with changes in pain-
evoked potentials but not oscillatory activities (Tiemann et al.,
2015).
Reports of placebo effects in healthy subjects were primarily
based on duration limited phasic pain (Atlas et al., 2009;
Benedetti, 2009). Phasic pain provides some important
methodological benefits (e.g., safe and easy to apply repeatedly),
but it is too short to faithfully simulate clinical pain, which is
rarely brief and exhibits an explicit onset of pain perception.
Therefore, several studies proposed tonic pain models, which are
crucial to model the pain experience in clinical settings (Le Pera
et al., 2000; Chang et al., 2001, 2002, 2003, 2004; Huber et al.,
2006; Dowman et al., 2008; Nir et al., 2010). One tonic painmodel
uses pain originating from deep tissue, such as intramuscular
infusions of capsaicin or hypertonic saline, which is most
frequently encountered in clinical practice pain (Apkarian et al.,
2005). The present study used a prolonged muscle infusion
of hypertonic saline to generate tonic muscle pain (Stohler
and Kowalski, 1999). Hypertonic saline was continuously
infused to maintain a relatively stable pain sensation based
on real-time feedback of subjective pain intensity (Stohler,
1992).
FIGURE 1 | Experimental design and subjective pain intensity
perception. (A) The experiment consisted of four order-fixed 20-min
conditions in two sessions. Session 1: (I) control, (II) pain; Session 2: (III)
control with placebo, (IV) pain with placebo. Innocuous and noxious
stimulations were respectively applied in control conditions (I and III) and pain
conditions (II and IV). (B) The subjective pain intensity (mean ± SEM) was
collected every 15 s for each condition from all placebo responders (N = 14).
We collected continuous EEG data during tonic muscle pain
to assess the effect of placebo treatment on: (1) the subjective
perception of tonic pain; (2) the electrophysiological oscillatory
activities; and (3) the correlations between changes in pain
perception and oscillatory activities.
MATERIALS AND METHODS
Subjects
The study included 19 subjects (3 females and 16 males, mean
age: 23 ± 2 years). All subjects were nonsmokers with no
personal history of any neurological or psychiatric disease. None
of the subjects had any history of chronic or acute pain up to
4 weeks before and during the study period, and none of the
subjects was on any medication. All subjects provided informed
consent, and the Human Research Ethics Committee of the
Shenzhen Institutes of Advanced Technology, Chinese Academy
of Sciences approved the experimental procedures.
Experimental Design
The experiment consisted of four order-fixed 20-min conditions
in two sessions (Figure 1A): session 1: (I) control, (II) pain;
and session 2: (III) control with placebo, (IV) pain with
placebo. Subjects were informed that the impending sequential
intramuscular injections were possibly painful or non-painful
before each session. Experiments were conducted in a silent
and separate room, and subjects were comfortably seated in
a chair. Subjects were required to rate the intensity of pain
perception every 15 s on a computer-controlled visual analog
scale (VAS) ranging from 0 to 10 (0: no pain; 10: the most
pain intensity imaginable) during all conditions. A moving
bar was used to indicate VAS ratings, which were displayed
on a monitor in front of the subjects. Subjects indicated the
intensity of pain perception by pressing a keyboard key to
stop the moving bar with their left hand (the moving bar
ascended one score per second). Subjects were asked to arbitrarily
choose given scores on the VAS every 15 s until their response
was sufficiently accurate to familiarize subjects with the rating
paradigm.
We used an automated stimulus delivery system in this
study. We used two 24-gauge needles, and each needle was
attached to a syringe through a disposable tube. The outline
of the masseter muscle was established during clenching. The
needles were inserted in bilateral masseter muscles to a depth
of approximately 1 cm. Prolonged innocuous stimulation was
introduced during control conditions (I and III) via infusions
of medication-grade isotonic saline (0.9% NaCl) in the right
masseter muscle. During pain conditions (II and IV), prolonged
noxious stimulation was introduced by infusing hypertonic
saline (5% NaCl) in the left masseter muscle. Automated syringe
infusion pumps controlled the infusions. Isotonic saline was
infused at a constant speed of 75 µl/min during innocuous
stimulation (1500 µl in total). Noxious stimulation included a
0.2-ml bolus infusion over 15 s at the beginning and subsequent
continuous infusions at variable speeds (2134 ± 930 µl in
total). The speed of infusion was adjusted using a computer-
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controlled closed-loop system based on the real-time feedback
of pain perception to ensure perceived pain intensity maintained
at an approximate VAS level of 5 (Zhang et al., 1993; Stohler
and Kowalski, 1999). The adaptive controller identified the
system dynamic response and proportional-integral-derivative
(PID) controller parameters from the subjects’ initial response
to the bolus infusion (Zhang et al., 1993). The intramuscular
infusion of hypertonic saline produced a deep aching sensation
that was similar to chronic muscle pain, and the generated
pain sensation disappeared 5–10 min after cessation of
the hypertonic saline infusion (Stohler and Kowalski, 1999;
Zubieta et al., 2005). Consecutive sessions were separated by
at least 10 min.
Subjects were infused with isotonic saline (0.9% NaCl)
via an antecubital intravenous port in their right upper limb
during all four conditions. However, the subjects were told
that the isotonic saline was replaced by a novel medication
named ‘‘Entacapone’’ prior to conditions with placebo (III and
IV), and they were further given the following clinical trial-
type instruction: ‘‘we are studying the analgesic effect of a
novel medication named ‘‘Entacapone’’, and it may or may
not ease your pain’’ (Zubieta et al., 2005; Scott et al., 2007).
The same infusion profile of noxious stimulation was applied
for pain (II) and pain with placebo (IV) for each subject
(Scott et al., 2008).
Subjects were instructed to fill out the Chinese version of the
Positive and Negative Affective Scale (PANAS; Watson et al.,
1988) and McGill Pain Questionnaire (SF-MPQ; Melzack, 1987)
after each condition (I–IV) to provide details of their subjective
perceptions of pain. The Chinese version of these questionnaires
exhibits acceptable reliability and validity (Huang et al., 2003; Li
et al., 2013).
Behavioral Data Analysis
The average rating of pain intensity across all rating points
(once every 15 s) was calculated for each subject during
each condition. Subjects who reported an increase in the
average rating of the intensity of pain perception to noxious
stimulation after the placebo treatment (II vs. IV) were classified
as nocebo responders, and the other subjects were classified
as placebo responders (Scott et al., 2008). Previous studies
reported that placebo and nocebo effects were associated
with opposite responses of dopamine and endogenous opioid
neurotransmission in a distributed network of cortical and
subcortical regions (Scott et al., 2008). Therefore, psychophysical
and electrophysiological data from nocebo responders were
excluded from subsequent analyses.
Psychophysical data analyses were performed as follows. The
ratings of pain perception, positive affect ratings (PANAS-P)
and negative affect ratings (PANAS-N) were compared across all
four conditions using a two-way repeated-measures analysis of
variance (RMANOVA), with ‘‘pain’’ (two levels: control vs. pain)
and ‘‘placebo’’ (two levels: without vs. with placebo) as factors.
Post hoc tests were performed when the interaction effect was
significant. Not all subjects finished the SF-MPQ questionnaire
after control conditions (I and III), so the total MPQ sensory
(MPQ-S) and affective (MPQ-A) scores of only pain conditions
(II and IV) were calculated for each subject. The scores were
compared between two pain conditions using a two-tailed paired
sample t-test.
EEG Recording and Data Analysis
Continuous EEG data were recorded using a Neuroscanr
Scan 4.2 (Neuroscan, Charlotte, NC, USA) amplifier and
128 Ag/AgCl electrodes mounted on an elastic cap (Quickapr,
Neuromedical supplies, Charlotte, NC, USA) according to the
extended international 10–20 system (Aslaksen et al., 2007).
The reference channel was located at the vertex, and all
channel impedances were kept lower than 10 kΩ. Extracranial
activity was continuously recorded with a 0.05 Hz and
100 Hz band-pass filter and was digitized at a sampling rate
of 1000 Hz. A notch filter was set to 50 Hz to reduce
electrical interference. Electro-oculographic (EOG) signals were
simultaneously recorded from four surface electrodes (one
pair over the upper and lower eyelids; the other pair placed
1 cm lateral to the outer corner of the left and right orbits)
to monitor ocular movements and eye blinks. Subjects were
instructed to relax and keep their eyes open during each
condition.
Preprocessing
EEG data were analyzed using Matlab (The Mathwork, Natick,
MA, USA) and EEGLAB1, which is an open source toolbox
running under the Matlab environment. Continuous EEG data
for each condition were down-sampled to 500 Hz and band-
pass filtered between 1 and 100 Hz. Continuous EEG data
contaminated by eye-blinks and movements were corrected
using an independent component analysis (ICA) algorithm
(Makeig et al., 1997; Jung et al., 2001; Delorme and Makeig,
2004). The de-noised EEG data were re-referenced to a common
average reference. EEG data collected during a short period of
30 s at the beginning and end of each condition were discarded
to exclude possible brain responses related to the sudden change
in stimulation.
EEG Spectral Analysis
Nineteen minutes of continuous EEG data from each subject and
condition were transformed to the frequency domain using a
discrete Fourier transform to yield amplitude spectra (in µV)
ranging from 1 to 100 Hz. The amplitudes of EEG oscillations
in the delta (0−4 Hz), theta (4−8 Hz), alpha (8−12 Hz), beta
(12−30 Hz), and gamma (30−100 Hz) bands were calculated for
each condition and electrode, and the first group of amplitude
spectra was obtained.
Previous studies generally used verbal pain perception
ratings. EEG data during ratings were excluded because of
the possible confounding factor of speaking. Subjects in this
experiment indicated the intensity of pain perception by pressing
a keyboard key to stop a moving bar with their left hand.
This pain rating procedure required a longer time than verbal
pain rating because the moving bar ascended one score per
second. We investigated whether the inclusion of the EEG
1http://sccn.ucsd.edu/eeglab
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data during pain perception was important for the extraction
of placebo-related modulation effects. Therefore, additional
separate analyses were performed with the EEG data during pain
perception rating and EEG data after rating. Pain perception
ratings were repeated once in every 15 s. Subjects pressed
a button when the moving VAS bar indicated their pain
intensity. Therefore, we partitioned the EEG data based on
the time point when the pain intensity rating was completed.
The original preprocessed continuous EEG data were segmented
into EEG epochs of 1 s, and the segmented EEG epochs
were transformed to the frequency domain for each subject
and each condition to facilitate the partition. The obtained
single-epoch amplitude spectra according to time period during
rating were averaged for each electrode and condition to
provide another group of amplitude spectra. The numbers
of segments during ratings were 2.60 ± 1.17, 5.39 ± 1.19,
2.25 ± 1.15 and 4.19 ± 0.70 in conditions I, II, III, and
IV, respectively. The obtained single-epoch amplitude spectra
according to time periods after VAS rating were also extracted
to provide a third group of amplitude spectra. The numbers
of segments after ratings were 12.40 ± 1.17, 9.61 ± 1.19,
12.75 ± 1.15 and 10.81 ± 0.70 in conditions I, II, III, and IV,
respectively.
All three groups of amplitude spectra were compared
across all four conditions using point-by-point two-way RM
ANOVA with ‘‘pain’’ (two levels: control vs. pain) and
‘‘placebo’’ (two levels: without vs. with placebo) as factors.
Considering the two-by-two experimental design, significant
interaction effect indicated the placebo effect. A permutation
test with 5000 iterations was used to construct the null
distribution of the max F-statistic across electrodes to control
for multiple comparisons. We identified the F-statistic that
corresponded to the 5% most extreme parts of the maximal
F distribution. We thresholded our original statistical maps
at that 5% level from the maximal F distribution (Maris and
Oostenveld, 2007). Compared with this F-statistic, higher F
value represented significant result after correction. Besides,
we calculated the corrected P value of our observed F value
by counting the proportion of the permutation distribution
as or more extreme than F. Results of main effects and
post hoc tests were presented when the interaction effect was
significant.
Correlation Analysis
The correlation coefficients and significance of placebo
responders were calculated between changes in the amplitude
of alpha oscillation measured at frontal-central electrode FCz
after placebo treatment (IV–II) and changes in: (1) subjective
intensity of pain perception to noxious stimulation; and (2)
psychophysical scores (i.e., PANAS and MPQ scores; II–IV).
Besides, in order to keep consistent with the two-by-two
experimental design, correlation analysis was also performed
with changes which were calculated according to the interaction
effect ((IV–II)–(III–I)) for alpha amplitude; ((II–IV)–(I–III)) for
subjective intensity).
RESULTS
Psychophysical Results
The subjective intensity of pain perception to noxious
stimulation increased after the placebo treatment (IV vs. II)
in five subjects (nocebo responders) and decreased in the
remaining 14 subjects (placebo responders). The intensity of
pain perception to noxious stimulation for placebo responders
revealed an overall declining tendency with increased stimulus
duration (II and IV; Figure 1B), which may be due to the
limitation of the maximum speed of hypertonic saline infusion.
In contrast, the intensity of pain perception to innocuous
stimulation was approximately a VAS level of 2 and increased
slightly with increased stimulus duration (I and III; Figure 1B),
which may be caused by the needle effect (Veerasarn and Stohler,
1992).
Table 1 summarizes the average ratings of subjective
pain intensity, PANAS scores, and MPQ scores for placebo
responders. The intensity of pain perception was significantly
modulated by the factors ‘‘placebo’’ (F(1,13) = 25.889, P = 0.000)
and ‘‘pain’’ (F(1,13) = 105.663, P = 0.0000) and the interaction
between two factors (F(1,13) = 5.748, P = 0.032; Figure 2C).
The decrease in pain intensity to noxious stimulation was
significant after placebo treatment (II vs. IV; P = 0.000), but
only marginally significant to innocuous stimulation (I vs.
III; P = 0.058). The PANAS-P scores were not significantly
modulated by the factor ‘‘pain’’ (F(1,13) = 1.050, P = 0.324)
or ‘‘placebo’’ (F(1,13) = 2.444, P = 0.142), or the interaction
between the two factors (F(1,13) = 0.918, P = 0.356). The
PANAS-N scores were significantly modulated by the factor
‘‘placebo’’ (F(1,13) = 8.050, P = 0.014) but not the factor
‘‘pain’’ (F(1,13) = 1.518, P = 0.240) or the interaction between
the two factors (F(1,13) = 1.194, P = 0.294). MPQ-S scores
decreased significantly in condition IV compared to condition II
(t(13) = 2.230, P = 0.044). In contrast, the MPQ-A scores were not
TABLE 1 | Psychophysical responses of placebo responders.
Pain Intensity PANAS-P PANAS-N MPQ-S MPQ-A
Condition I 2.16 ± 1.17 23.14 ± 6.13 14.64 ± 3.88 − −
Condition II 4.93 ± 1.21 21.36 ± 6.49 16.50 ± 5.49 9.93 ± 6.06 6.21 ± 3.95
Condition III 1.79 ± 1.11 20.64 ± 6.38 13.43 ± 3.16 − −
Condition IV 3.75 ± 0.71 20.50 ± 6.47 13.36 ± 2.95 3.36 ± 2.27 2.07 ± 1.64
Mean ± 1 SD of psychophysical measures during conditions in the absence and presence of placebo in 14 placebo responders. Pain intensity refers to the average
ratings of momentary pain acquired every 15 s.
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significantly different between conditions II and IV (t(13) = 1.906,
P = 0.079).
Electrophysiological Results
Frequency analyses of the 19-min continuous EEG data
revealed that the group level scalp topographies of alpha
oscillations were maximal at bilateral posterior parietal and
occipital regions in all four conditions (Figure 2A). Point-
by-point two-way RM ANOVA revealed that electrode FCz
exhibited a significant interaction effect on the amplitudes of
alpha oscillations after correction for multiple comparisons
(Figure 2B). The amplitudes of alpha oscillations at FCz
were 6.56 ± 2.19 µV, 5.70 ± 1.80 µV, 6.52 ± 2.23 µV,
and 6.18 ± 2.04 µV in conditions I, II, III, and IV
respectively. The amplitudes of alpha oscillations at FCz were
significantly modulated by the factor ‘‘pain’’ (F(1,13) = 13.886,
P = 0.040, corr.) and the interaction between the two factors
(F(1,13) = 13.003, P = 0.046, corr.; Figure 2D), but not
by the factor ‘‘placebo’’ (F(1,13) = 1.483, P = 0.864, corr).
Post hoc tests revealed that the amplitudes of alpha oscillations
were significantly larger in condition IV than condition II
(P = 0.005), but no significant difference was observed between
the amplitudes of alpha oscillations in conditions I and III
(P = 0.846).
Frequency analyses results of EEG data during pain
perception ratings revealed that electrode FCz exhibited a
FIGURE 2 | Evidence showing the effect of placebo treatment from behavioral and EEG data. (A) Group level scalp topographies of alpha oscillations
(8–12 Hz) of different experimental conditions. (B) Group level spectra (measured at FCz) of different experimental conditions. Scalp topography showing the
significant interaction between the factors “pain” and “placebo” on the amplitudes of alpha oscillations at FCz is displayed in the insert. (C) Significant interaction
effect between the factors “pain” and “placebo” was observed on the average ratings of pain intensity across all rating points (once every 15 s; left). (D) The
amplitudes of alpha oscillation (measured at FCz). Each dot represents the mean value from one condition, and error bars represent, for each condition, ± SEM
across subjects (F: F value of the interaction effect between the factors “pain” and “placebo”; corr.: corrected for multiple comparisons). (E) Significant correlation
was observed between decrease in pain intensity during noxious stimulation after placebo treatment (II–IV) and the increase in the amplitude of alpha oscillation
measured at FCz (IV–II). Each dot represents a value from each subject, and black line represents the best linear fit.
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trend toward significant interaction effect between the factors
‘‘pain’’ and ‘‘placebo’’ on the amplitudes of alpha oscillation
(F(1,13) = 8.065, P = 0.014, uncorr., P = 0.138, corr.; left and
middle panels of Figure 3A). Post hoc tests revealed that the
amplitudes of alpha oscillations were significantly larger in
condition IV than condition II (P = 0.004), but no significant
difference was observed between conditions I and III (P = 0.638).
Analysis results of EEG data after VAS ratings revealed that the
interaction effect was not significant (F(1,13) = 4.564, P = 0.222,
corr.; left and middle panels of Figure 3B).
Correlation between Psychophysical and
Electrophysiological Data
First, the correlation analysis was performed with changes
between two pain conditions (II vs. IV). Significant positive
correlation was observed between increases in the amplitudes
of alpha oscillations measured at FCz after placebo treatment
and decreases in: (1) subjective intensity of pain perception
(R = 0.611, P = 0.020; Figure 2E); (2) MPQ-S scores (R = 0.641,
P = 0.014); and (3) MPQ-A scores (R = 0.594, P = 0.025)
when EEG data of the entire 19-min continuous EEG data were
included. The correlation between alpha oscillation increases and
pain perception decreases was also significant when only EEG
data during pain perception rating were included (R = 0.584,
P = 0.028). The correlation was marginally significant when only
EEG data after pain perception rating were included (R = 0.524,
P = 0.055). Secondly, no significant correlation was observed
when the correlation analysis was performed with the interaction
terms (P > 0.05).
DISCUSSION
The present study described an active placebo effect on
electrophysiological alpha oscillations during 20 min of tonic
muscle pain. We observed placebo effects on the subjective
intensity of pain perception to noxious stimulation. Placebo
induced significant increases or a trend toward significant
increases in the amplitude of alpha oscillation during tonic
muscle pain in frontal-central regions when EEG data during
pain perception ratings were not excluded. The decreases
in the subjective intensity of pain perception to noxious
stimulation after placebo treatment and the increases in the
amplitude of alpha oscillation were significantly correlated.
These findings suggest that placebo modulation in cognitive
appraisal/experience of tonic muscle pain were effectively
indexed by electrophysiological alpha oscillations, which served
as additional evidence for the expectancy-based placebo
mechanism (Wager et al., 2004; Zubieta et al., 2005; Scott et al.,
2007; Atlas and Wager, 2012).
FIGURE 3 | Evidence showing the effect of placebo treatment from the partitions of EEG data during pain perception rating and after rating.
(A) A trend toward significant interaction effect was identified from frequency analyses including EEG data during the rating period (left panel); the mean values of the
amplitudes of alpha oscillation (measured at FCz) from each condition are shown (F: F value of the interaction effect between the factors “pain” and “placebo”; corr.:
corrected for multiple comparisons; middle panel); a significant correlation was observed between decrease in pain intensity during noxious stimulation after placebo
treatment (II–IV) and the increase in the amplitude of alpha oscillation measured at FCz (IV–II; right panel). (B) No significant interaction effect was identified from
frequency analyses that included EEG data of the time periods after rating (left panel); the corresponding results of mean amplitude values are shown (middle panel);
marginally significant correlation was observed (right panel).
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Numerous neuroimaging studies, including fMRI and PET
studies of healthy subjects and clinical patients, revealed several
cortical and subcortical regions that were mediated by placebo
treatment (Meissner et al., 2011). The placebo analgesia also
suppressed pain-induced responses in thalamus, insula, and ACC
(Wager et al., 2004; Bingel et al., 2006; Kong et al., 2006; Price
et al., 2007; Eippert et al., 2009). Assessments of the placebo
effect to LEPs revealed a significant decrease in P2 amplitude,
which was partially explained by the reduction in reported pain
perception (Wager et al., 2006). The P2 in LEPs is highly likely
generated from the ACC (Garcia-Larrea et al., 2003), and the
decrease in P2 amplitude is consistent with the suppression
of pain-induced responses in the ACC, which provides solid
evidence that placebo analgesia is likely achieved via modulation
of the emotional and cognitive components of pain (primarily
coded by the ACC; Wiech et al., 2008; Tracey, 2010).
The placebo modulation effect that we observed supports
the existence of a placebo effect on brain oscillation. The
placebo treatment-induced changes in alpha oscillatory activities
were maximal at frontal-central electrodes, which suggests the
contribution of ACC to the generation of placebo-induced
changes in alpha oscillations and confirms the modulation
of placebo on the affective and cognitive components of
pain that were observed to previous fMRI and PET studies
(Wiech et al., 2008; Zubieta and Stohler, 2009; Tracey, 2010).
Notably, the suppression of alpha amplitudes may reflect cortical
activation or disinhibition of the corresponding neural networks
(Pfurtscheller et al., 1996; Pfurtscheller and Lopes da Silva, 1999;
Hu et al., 2013). For example, increased cellular excitability
in thalamo-cortical systems was reflected by a decrease in
alpha amplitude in EEG (Steriade and Llinás, 1988). Thus,
the significant increase of alpha amplitude at frontal-central
regions after placebo treatment may indicate an inhibition
of cortical areas (including ACC) that are involved in pain
processing (e.g., cognitive appraisal of tonic pain). However,
we cannot make any firm conclusions about the contribution
of ACC to the generation of placebo-induced changes in alpha
oscillations without source analyses. We also cannot exclude the
possible contribution of other neural sources (e.g., operculo-
insular cortex) despite the performance of an EEG source analysis
because of the limited spatial resolution of the EEG technique
and the inverse problem in EEG source analysis (Michel et al.,
2004). Hopefully, these issues may be effectively solved using the
simultaneous EEG-fMRI technique, which was effectively used to
extract fMRI activations that were significantly modulated by the
alpha amplitude in EEG (Feige et al., 2005).
Only two published studies reported placebo treatment effects
on brain alpha oscillatory activity. One study related alpha
activity to placebo analgesia and reported a placebo-associated
increase in alpha oscillations (Huneke et al., 2013). However,
this study recorded alpha activity during resting states after
placebo induction (Huneke et al., 2013). Another study reported
that phasic pain-induced alpha responses were not sensitive
to placebo manipulation using changes in stimulus intensity
(Tiemann et al., 2015). This study did not include EEG data
during pain perception (Tiemann et al., 2015). The placebo
effect was derived from the cognitive and affective processing
of pain perception, which may be more promising during the
rating period. The alpha suppression in response to tonic pain
primarily reflects high-level cognitive processing, and attention
modulation may significantly affect it (Peng et al., 2014). Placebo
treatment-related modulation effects of alpha oscillations may
be better captured when subjects are asked to focus on their
pain perception and report their pain intensity. Consequently, we
observed significant modulation effects of placebo treatment and
a positive correlation between placebo-induced pain decrease
and increase in alpha amplitude when the pain perception
evaluating period was included.
This study generated tonic muscle pain via an intramuscular
infusion of hypertonic saline to produce a deep aching that
was similar to the muscle pain experienced in clinical situations
(Stohler and Kowalski, 1999). Our understanding of the neural
mechanisms of pain were primarily based on the brain activation
of phasic cutaneous pain, which involves fewer methodological
challenges (e.g., easier to present several times to achieve a
high signal-to-noise ratio of the brain responses) compared
to tonic pain (Apkarian et al., 2011). However, chronic pain
is normally prolonged and originates from deep tissue (e.g.,
muscle and viscera) in clinical practice (Apkarian et al., 2005;
Schreckenberger et al., 2005). Therefore, the tonic muscle pain
achieved by intramuscular infusion of hypertonic saline was
used in the present study. The automated stimulus delivery
system produced a prolonged, relatively stable muscle pain and
achieved a better simulation of the pain experience in clinical
settings, which may be important to establish the connection
between placebo analgesic studies conducted in experimental
settings (healthy subjects) and clinical practice (chronic pain
patients).
There are several limitations to this study. First, this study
consisted of fixed-order sessions (session 1: conditions I and
II, session 2: conditions III and IV). Session 1 was always
performed before session 2 because the individual infusion
profiles used in condition IV should be identical to condition
II. We cannot exclude the confounding factors of mental
fatigue-induced alpha oscillation changes in this fixed-order
and longer-lasting experiment. Experiments with prolonged
stimulation are difficult to control as well as experiments using
phasic stimulation. Mental fatigue and its influence on the
measures of brain oscillation should be carefully considered.
Spectral measures of brain oscillations were investigated to
reflect changes in mental state in longer-lasting experiments.
Several EEG measures were proposed to be valid and reliable
indicators of mental fatigue, including a characterized shift
of EEG power towards lower-frequency bands (delta, theta
and alpha) and decrease in higher-frequency bands (Lal and
Craig, 2002; Wascher et al., 2014). The amount of alpha
suppression declined with time on task (Wascher et al., 2014).
An increase in alpha power may reflect the increased effort
and the difficulty of the subjects to maintain a state of alert
wakefulness (Wascher et al., 2014). The significant correlation
between the differences in pain perception and alpha amplitude
was observed when the differences were calculated between two
pain conditions II and IV. But no significant correlation could
be observed when the differences were calculated according
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to the interaction effect. Small sample size and fixed-order
design might be some of those factors that contributed to this
problem. Therefore, the correlation between the effect size of
placebo analgesia in pain perception and alpha amplitude require
further investigation using a randomized design and within-
subject correlation analysis may offer more solid evidence.
Second, the saline infusions in the control conditions and
the pain conditions occurred on different sides. Therefore,
we could only focus on the results of central electrodes in
this study. The acquisitions of EEG data involve up to a few
hundred electrodes positioned on the scalp, which together
with volume conduction through the head results in a poor
spatial resolution (Michel et al., 2004). The spreading effect
from the lateral electrodes should be taken into consideration
when interpreting the observed effects at the central electrodes.
Third, the number of segments was different for different
conditions when performing additional analyses with EEG data
during and after ratings. This difference may be a confounding
factor for comparisons of the amplitude spectrum among four
conditions. Fourth, we only performed multiple comparisons
correction for the number of electrodes (Schulz et al., 2015),
but the correction for point-by-point analysis should account for
the number of electrodes and the number of frequency bands
(Peng et al., 2014). Previous studies reported an association of
placebo and nocebo effects with opposite responses of dopamine
and endogenous opioid neurotransmission in a distributed
network of cortical and subcortical regions (Scott et al., 2008),
and possible electrophysiological responses that are oppositely
involved in placebo and nocebo effects should be assessed in the
future.
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